Filter posts

Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the …

WILEX receives approval for Phase I trial

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German …

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. …

Provectus starts Phase 1 trial for liver cancer treatment

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver …

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug …

U.S. Navy to fund Vical's H1N1 vaccine

The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for …

Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) …

Intarcia presents positive results of Type 2 Diabetes study

Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 …

MDRNA patent allowance for siRNA

MDRNA, Inc. (NASDAQ: MRNA) announced that the U.S. Patent and Trademark Office (USPTO) has issued …

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. complete merger

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) …